Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism

Inclusion Criteria: * Age at or above 18 years * End stage renal disease on regular maintenance haemodialysis or peritoneal dialysis for at least 3 months * iPTH level of 300 pg/ml or greater at baseline * Written informed consent by subject or guardian * Female patients will either be post-menopausal for more than 2 years, surgically sterile or if of childbearing age, using double contraception Exclusion Criteria: * Baseline calcium value more than 2.87 mmol/L * Baseline Ca x P of greater than 5.63 mmol2/l2 * Positive for HBsAg or Hepatitis C with raised ALT twice above upper limit of normal or evidence of liver cirrhosis * Clinically significant gastrointestinal disease * History of allergic reaction to calcitriol or other vitamin D compounds * Inability or unwillingness to provide written consent. * Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator. * Pregnancy, breastfeeding or use of non-reliable method of contraception. * Use of medications prohibited prior to randomization such as ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir * Necessity for calcitonin, biphosphonates, maintenance oral or intravenous glucocorticoid or cinacalcet or other drugs that may affect calcium or bone metabolism. * Alcohol or substance abuse within 6 months prior to screening * Other medical condition which, in the investigator's judgement, may be associated with increased risk to the subject or may interfere with study assessments or outcomes. * Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to screening visit. * If PD subjects had active peritonitis within one month prior to the screening visit